Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 2;52(9):1550–1563. doi: 10.1038/s12276-020-00493-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a, b Comparison of methylation levels of pDMR for CYTIP between responders (R) and non-responders a and those for TNFSF8 b in the validation cohort. c Comparison of the PD-L1 expression level between responders (R) and non-responders (NR) in the validation cohort. d, e Proportion of patients with objective response (blue) or no objective response (red) to anti-PD-1 therapy for the methylation level threshold of pDMR for CYTIP (40%) or that for TNFSF8 (50%), respectively. “Pos” indicates patients predicted to respond, and “Neg” indicates those predicted to not respond to anti-PD-1 therapy. f Analysis as for d, e with 1% of PD-L1 IHC expression level. g Analysis as for d, e with combined use of pDMRs for CYTIP and TNFSF8.